SOHO SPOTLIGHT

SOHO SPOTLIGHT

By society of hematologic oncologyScienceEducationLife Sciences
Download on the App Store

SOHO SPOTLIGHT episodes

  • The Real PARADIGM Shift in AML: Clearing the Pathway to Transplant

    Host: Gail J. Roboz, MD, Weill Cornell Medicine
    Guest: Aravind Ramakrishnan, MD, St. David’s South Austin Medical Center

    This episode is supported by the National Marrow Donor Program (NMDP)

    Episode Summary:
    For years, allogeneic stem cell transplant was seen mainly as an option for younger patients with AML who could tolerate intensive chemotherapy. That picture is changing fast. Leukemia specialist, Dr. Gail Roboz and transplant physician, Dr. Aravind Ramakrishnan, make the case that every patient who might be a reasonable transplant candidate should be connected with a transplant team early, with HLA typing done at diagnosis.

    HOST:
    Gail J. Roboz, MD
    Professor of Medicine
    Director, Leukemia Program, Weill Cornell Medicine
    NewYork-Presbyterian Hospital

    GUEST:
    Aravind Ramakrishnan, MD
    Adult Bone Marrow Transplant Medical Director, St. David’s South Austin Medical Center
    Texas Transplant Institute, Center for Blood Cancers and Oncology

    Topics Covered:

    • Getting patients with AML and MDS to transplant sooner
    • HLA typing at diagnosis and early referral to the transplant team
    • Why transplant is a planned procedure, not an emergency
    • The graft-versus-leukemia effect
    • NMDP’s Pathways to Transplant program: free HLA typing and support for community oncologists
    • Wider donor options: mismatched unrelated and haploidentical donors, and why donor age matters
    • Transplant for older patients: fitness over age
    • Azacitidine-venetoclax induction as a route to transplant
    • Keeping the transplant conversation with patients short and simple

    Related Resources:

    • NMDP Pathways to Transplant: Support for HCPs and patients
      https://network.nmdp.org/services-support/hematology-oncology/pathways-to-transplant
    • HCT consultation guidelines and outcomes
      https://network.nmdp.org/services-support/hematology-oncology/consultation-guidelines-outcomes
    • Local provider partnership program
      https://network.nmdp.org/services-support/hematology-oncology/pathways-to-transplant/local-provider-partnership-program

    Connect With Us:

    • Website: Home
    • Newsletter: SOHO Insider
    • YouTube
    • Facebook
    • X (Twitter)
    • LinkedIn
    • Instagram

    The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.

    21 min
  • Optimizing the Outcomes for Diffuse Large B-cell Lymphoma in the Community

    Host: Joshua Brody, MD, Icahn School of Medicine at Mount Sinai
    Guest: Jeremy Abramson, MD, MMSC, Harvard Medical School

    This episode is supported by an educational grant from Genentech.

    Episode Summary:
    Until recently, patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who couldn't have a transplant had no curative options. Today, nearly every patient in the second line can be treated with curative intent. Dr. Josh Brody and Dr. Jeremy Abramson walk through the options: CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and combinations of these. They cover how to choose the optimal therapy for transplant-ineligible patients, especially when CAR T is not an option or if the disease is progressing rapidly. They also discuss the role of MRD testing in monitoring treatment response, long-term infection risk with bispecific antibodies, and practical tips for coordination of care between academic centers and community oncologists.

    HOST:
    Joshua Brody, MD
    Director, Lymphoma Immunotherapy Program
    Icahn School of Medicine at Mount Sinai
    Hess Center for Science and Medicine
    @JoshuaBrodyMD
    LinkedIn

    GUEST:
    Jeremy Abramson, MD, MMSC
    Director, Jon and Jo Ann Hagler Center for Lymphoma
    Professor of Medicine, Harvard Medical School
    LinkedIn

    Topics Covered:

    • Second-line options for transplant-ineligible relapsed/refractory DLBCL
    • CAR T-cell therapy: curative potential and barriers to access
    • Bispecific antibody regimens: glofitamab-GemOx (STARGLO), epcoritamab-GemOx, and mosunetuzumab-polatuzumab (SUNMO)
    • ADC regimen: Polatuzumab-R-GemOx (POLARGO)
    • Bridging therapy before CAR T-cell therapy: low-dose radiation, systemic options, and investigational glofitamab-GemOx regimen
    • Minimal residual disease (MRD) testing and the ALPHA3 trial
    • Combining ADCs and bispecific antibodies: loncastuximab tesirine, glofitamab and mosunetuzumab or polatuzumab (LOTIS-7 trial)
    • Toxicities: CRS, hypogammaglobulinemia, and infection risk
    • Coordinating care between academic centers and community cancer centers

    Related Resources:

    1. Slides from SOHO Breakthroughs in Blood Cancers, Aggressive B-cell lymphomas, Julie Vose, MD
    2. What is the 2025 treatment landscape in DLBCL? Jason Westin, MD
    3. What are the areas of unmet needs in large cell lymphoma? Loretta Nastoupil, MD

    Connect With Us:

    • Website: Home
    • Newsletter: SOHO Insider
    • YouTube
    • Facebook
    • X (Twitter)
    • LinkedIn
    • Instagram

    The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.

    42 min
  • Optimizing Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) with CAR-T Cell Therapies

    Host: Nicholas J. Short, MD, MD Anderson Cancer Center
    Guest: Jae Park, MD, Memorial Sloan Kettering Cancer Center

    This podcast episode is supported by Autolus.

    Episode Summary:
    This episode of SOHO Spotlight explores the evolving role of CD19 CAR T-cell therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), highlighting the importance of early referral, patient selection criteria, and differences between currently available CAR T products. Dr. Jae Park and Dr. Nicholas Short discuss emerging evidence supporting safer outpatient treatment, individualized decisions regarding stem cell transplant after CAR T therapy, and the potential for CAR T to move into earlier lines of treatment, with the goal of improving long-term outcomes while reducing the need for intensive chemotherapy and transplantation.

    HOST:
    Nicholas J. Short, MD
    Associate Professor
    MD Anderson Cancer Center
    Houston, Texas, USA

    Dr. Nicholas J. Short is an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. He is a nationally recognized leukemia specialist whose research focuses on acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), measurable residual disease (MRD), and the development of novel immunotherapy-based treatments.

    Connect with Dr. Short:

    • Website
    • LinkedIn
    • @NicholasShortMD

    GUEST:
    Jae Park, MD
    Chief, Cellular Therapy Service
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York, USA

    Dr. Jae Park is Chief of the Cellular Therapy Service and Director of the Adult Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering Cancer Center. An internationally recognized expert in cellular therapies and immunotherapy for hematologic malignancies, his research focuses on developing safer and more effective CAR T-cell therapies to improve outcomes for patients with leukemia.

    To view all resources for this episode, view the episode page HERE.

    Connect With Us:

    • Website: Home
    • Newsletter: SOHO Insider
    • YouTube
    • Facebook
    • X (Twitter)
    • LinkedIn
    • Instagram

    The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.

    19 min

About SOHO SPOTLIGHT

From the publisher's feed

The official educational podcast of the Society of Hematologic Oncology. Expert conversations on the latest in leukemia, lymphoma, myeloma, and beyond — plus practical guidance and clinical updates…